DC BeadM1™: towards an optimal transcatheter hepatic tumour therapy

Andrew L. Lewis, Matthew R. Dreher, Vincent OʼByrne, David Grey, Marcus Caine, Anthony Dunn, Yiqing Tang, Brenda Hall, Kirk Fowers, Carmen Gacchina Johnson, Karun Sharma, Bradford J. WoodJournal of Materials Science Materials in Medicine 2015 · DOI

Abstract

Clinical use of DC Bead™ loaded with doxorubicin (DEBDOX™) or irinotecan (DEBIRI™) for treating liver tumors is showing great promise. Recently, there has been a shift toward smaller bead size ranges to improve tumor penetration and drug delivery. This study characterizes DC BeadM1™ (70–150 µm), a new size range designed for increased delivery in the distal vasculature. Using an in vitro penetration model and in vivo imaging, we demonstrate that these smaller beads provide greater distal volume penetration and more uniform drug coverage compared to traditional 100–300 µm beads, potentially allowing for higher therapeutic doses in both hypervascular and hypovascular tumors.

Introduction

Transarterial chemoembolization (TACE) is a standard treatment for liver cancer, utilizing chemotherapeutic-loaded beads to simultaneously block blood flow (embolization) and provide sustained drug release directly into malignant tissue. Historically, larger beads (100–700 µm) were preferred, but these often occlude proximal vessels, leaving distal tumor regions undertreated. While smaller beads offer deeper penetration, they must be carefully sized to avoid "shunting" into healthy organs. This paper evaluates the performance of the 70–150 µm DC BeadM1™ range as a potential "sweet spot" for efficacy and safety.

Methodology

The researchers compared the new DC BeadM1 (70–150 µm) against the established DC Bead (100–300 µm) using several models:

  1. In Vitro Penetration Model: A custom "wedge" geometry tapering from 555 µm to 25 µm simulated narrowing blood vessels under physiological pressure (40 mmHg).
  2. Drug Loading & Elution: Beads were loaded with doxorubicin or irinotecan to measure uptake and release kinetics under "pseudo-sink" conditions.
  3. In Vivo Imaging & Microscopy: Radiopaque bead versions were evaluated in rabbit VX2 tumor and swine liver models using micro-CT (µ-CT) for 3D distribution and epifluorescent microscopy to visualize drug diffusion.
Schematic of the in vitro penetration model (A, B) used to simulate bead distribution in tapering vasculature.

Key Insights and Results

Enhanced Distal Penetration

The in vitro wedge model revealed that while both 70–150 µm and 100–300 µm beads eventually reached similar ultimate depths, the smaller DC BeadM1™ achieved a significantly higher density of penetration in distal vessels. Larger beads tended to cause sporadic clogs, whereas smaller beads created a more uniform "leading edge" of embolization.

Drug Kinetics and Coverage

  • Loading and Elution: DC BeadM1™ loaded drugs slightly faster due to a higher surface-area-to-volume ratio. However, elution kinetics remained nearly identical to the 100–300 µm range, ensuring consistent drug delivery behavior.
  • Histological Density: In vivo analysis showed a 2.6-fold increase in the number of beads per vessel when using the 70–150 µm range. This higher bead density translates to a larger "drug penumbra"—the zone of effective drug concentration surrounding the beads.
Microscopic visualization of DC Bead samples across different size ranges and drug loading states (red indicates doxorubicin loading).

The Stiffness Factor

Interestingly, drug loading increases bead stiffness. While smaller beads are inherently more mobile, this increased stiffness acts as a mechanical counterbalance. Despite this, the 70–150 µm range consistently outperformed larger counterparts in filling peripheral vessels.

Discussion and Clinical Implications

The study indicates that DC BeadM1™ permits an increased drug dose to be administered to tumors by filling smaller peripheral vessels more efficiently. Early clinical correlations suggest that this improved distal coverage may lead to higher objective tumor response rates and a lower incidence of post-embolization syndrome.

Limitations

The primary risk with smaller beads is non-target embolization. Precise interventional techniques are required to prevent migration to unintended organs. Additionally, while the in vitro wedge model provides valuable mechanical data, it cannot fully replicate the complex, branching architecture of human tumor vasculature.

Conclusion

DC BeadM1™ (70–150 µm) represents a significant advancement in TACE therapy. By providing deeper, more uniform penetration and increased drug coverage without altering elution kinetics, these smaller beads offer a promising path toward optimizing liver tumor treatment.

Summary updated

Abstract

Clinical use of DC Bead™ loaded with doxorubicin (DEBDOX™) or irinotecan (DEBIRI™), for the treatment of primary and secondary tumours of the liver respectively, is showing great promise. Recently there has been a tendency to select smaller bead size ranges to treat tumours in an effort to allow more drug dose to be administered, improve tumoural penetration and resultant drug delivery and tumour coverage. Herein we describe the development and performance characterisation of a new DC Bead size range (DC BeadM1 (TM), 70-150 μm) capable of an increased bead delivery in the distal vasculature, corresponding to greater tumour coverage and drug dose delivered. Both unloaded and drug loaded DC BeadM1 were shown to have a greater density of distal volume of penetration although the ultimate distal level of penetration was the same as that of the 100-300 µm beads in an in vitro penetration model. Elution of doxorubicin was slower than irinotecan elution, but it was similar when comparing the same drug elution from 70 to 150 µm compared to 100-300 µm beads. Radiopaque versions of 70-150 and 100-300 µm beads were prepared in order to evaluate distribution ex vivo using µ-CT and doxorubicin distribution using epifluorescent microscopy. Liver distribution of the radiopaque versions of the beads was shown to be more distal and efficient at filling smaller vessels with the DC BeadM1 and correspondingly more beads were found per vessel histologically with a larger area of drug coverage with the smaller size range. This study indicates that the smaller (70-150 μm) beads should permit an increased dose of drug to be administered to both hypervascular and hypovascular tumours as compared to 100-300 µm beads.
BibTeX
@article{lewis2015dc,
  author = {Andrew L. Lewis and Matthew R. Dreher and Vincent OʼByrne and David Grey and Marcus Caine and Anthony Dunn and Yiqing Tang and Brenda Hall and Kirk Fowers and Carmen Gacchina Johnson and Karun Sharma and Bradford J. Wood},
  title = {{DC BeadM1™: towards an optimal transcatheter hepatic tumour therapy}},
  journal = {Journal of Materials Science Materials in Medicine},
  year = {2015},
  doi = {10.1007/s10856-015-5629-6},
}
Figure